

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vinginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR ATTORNEY DOC		CONFIRMATION NO.
09/803,317	803,317 03/09/2001 Ruoying Tan		6514-090US1 7596	
24353 7	590 05/01/2003			
	FIELD & FRANCIS	EXAMINER		
200 MIDDLEF SUITE 200	FIELD RD	FRIEND, TOMAS H F		
MENLO PARK, CA 94025			ART UNIT	PAPER NUMBER
			1639	
			DATE MAILED: 05/01/2003	Ç

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	n No.	Applicant(s)			
Office Action Summary		09/803,317	,	TAN ET AL.			
		Examiner		Art Unit			
		Tomas Frie	end	1639			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1)⊠							
2a)□		is action is r					
3)							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>							
4)⊠ Claim(s) <u>1-26</u> is/are pending in the application.							
,	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)□	Claim(s) is/are allowed.						
6)□	6)☐ Claim(s) is/are rejected.						
7)	7) Claim(s) is/are objected to.						
	Claim(s) <u>1-26</u> are subject to restriction and/or e	election requ	iirement.				
	ion Papers						
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	:		(PTO-413) Paper No(s) atent Application (PTO-152)			

Application/Control Number: 09/803,317

Art Unit: 1639

## **Detailed Action**

## Status of the Application

Receipt is acknowledged of an information disclosure statement on 09 March 2001 (Paper No. 5).

### Status of the Claims

Claims 1-26 are pending in the present application and are subject to restriction and election of species requirements.

#### Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-17, drawn to a method of identifying a nucleic acid encoding a signal sequence, classified in class 435, subclass 91.41.
  - II. Claims 18-22, drawn to a high throughput method of identifying a cDNA which encodes a secreted protein, classified in class 435, digest 17.
  - III. Claims 23-26, drawn to a vector for identifying a cDNA insert encoding a protein, classified in class 435, subclass 320.1.

The inventions are distinct, each from the other because:

2. Inventions III and Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that

Application/Control Number: 09/803,317 Page 3

Art Unit: 1639

product (MPEP § 806.05(h)). In the instant case the vector of Invention III can be used in either of the methods of Inventions I or II. The methods of Inventions I and II can be practiced using a vector different from that of Invention III such as a vector lacking a eukaryotic promoter.

- 3. Inventions I and II are different and patentably distinct methods because they involve different method steps, require different reactions and/or conditions, and/or produce different results. For example, the method of invention I requires a single cDNA, while the method of Invention II requires a plurality of cDNAs. The method of Invention II requires that the introduction of cDNA into a vector produces a cDNA-β-lactamase fusion, not required in the method of invention I.
- 4. Because these inventions are distinct for the reasons given above and
  - a. have acquired a separate status in the art as shown by their different classification;
  - b. have different and separately burdensome: manual and/or computer: structure, name and bibliographical searches; and
  - c. have divergent subject matter, restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under CFR 1.17(h).

### **Election of Species**

6. This application contains claims directed to patentably distinct species of the claimed invention. In addition to electing one of Inventions I-III, applicant is required to elect an ultimate species of vector that identifies the promoters and leaderless secretable selection protein present in and encoded by the vector.

Application/Control Number: 09/803,317

Art Unit: 1639

7. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Tomas Friend**, telephone number (703) 308-4548. The examiner's schedule is an increased flex-time schedule.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (703) 306-3217. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-2742.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist at (703) 308-1235.

Tomas Friend, Ph.D. 26 April 2003

ANDREW WANG
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600